Paid Clinical Trials Billings
Discover 142 paid clinical trials in Billings, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Research Study to Advance the CF Therapeutics Pipeline for People Without ModulatorsA Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Sponsor:
Nicole Hamblett
Location:
Code:
NCT06504589
Conditions
Cystic Fibrosis
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Sponsor:
Shanghai Henlius Biotech
Location:
Code:
NCT05468489
Conditions
Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Serplulimab + chemotherapy (carboplatin-etoposide)
Atezolizumab + chemotherapy (carboplatin-etoposide)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCINBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Sponsor:
Inhibrx Biosciences, Inc
Location:
Code:
NCT06295731
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
INBRX-106
Pembrolizumab
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
Sponsor:
Vertex Pharmaceuticals Incorporated
Location:
Code:
NCT06506773
Conditions
Cystic Fibrosis
Eligibility Criteria
Sex: All
Age: 0 - 6
Healthy Volunteers: Not accepted
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03866382
Conditions
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerTesting the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04164082
Conditions
Bladder Flat Urothelial Carcinoma In Situ
Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 0is Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy
Biospecimen Collection
Computed Tomography
Cystoscopy
Gemcitabine Hydrochloride
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT06116682
Conditions
Lung Non-Small Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Amivantamab
Biospecimen Collection
Computed Tomography
Magnetic Resonance Imaging
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Sponsor:
AbbVie
Location:
Code:
NCT06291220
Conditions
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Obinutuzumab
ABBV-453
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryUsing Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05111574
Conditions
Anal Melanoma
Bladder Melanoma
Cervical Melanoma
Esophageal Melanoma
Gallbladder Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography